Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NCTN: Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

ABSTRACT: NCTN: Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

PROVIDER: PRJNA1288585 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

NCTN: Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

Project description:NCTN: Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

| PRJNA1288586 | ENA

NCTN: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

Project description:NCTN: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

| PRJNA1288575 | ENA

NCTN: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

Project description:NCTN: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

| PRJNA1288576 | ENA

Circulating Tumor DNA in Intermediate Risk Rhabdomyosarcoma

Project description:Circulating Tumor DNA in Intermediate Risk Rhabdomyosarcoma

| PRJNA823798 | ENA

Circulating Tumor DNA in Intermediate Risk Rhabdomyosarcoma

Project description:Circulating Tumor DNA in Intermediate Risk Rhabdomyosarcoma

| PRJNA823799 | ENA

Copy number profiling of 556 high-risk neuroblastoma patients using aCGH or SNP arrays

Project description:Purpose: Neuroblastoma is characterized by substantial clinical heterogeneity. Despite intensive treatment, the survival rates of high-risk neuroblastoma patients are still disappointingly low. Somatic chromosomal copy number aberrations have been shown to be associated with patient outcome, particularly in low- and intermediate-risk neuroblastoma patients. To improve outcome prediction in high-risk neuroblastoma, we aimed to design a prognostic classification method based on copy number aberrations. Methods: In an international collaboration, normalized high-resolution DNA copy number data (arrayCGH and SNP arrays) from 556 high-risk neuroblastomas obtained at diagnosis were collected from nine collaborative groups and segmented using the same method. We applied logistic and Cox proportional hazard regression to identify genomic aberrations associated with poor outcome. Results: In this study, we identified two types of copy number aberrations that are associated with extremely poor outcome. (i) Distal 6q losses were detected in 5.9% of patients and were associated with a ten-year survival probability of only 3.4%. (ii) Amplifications of regions not encompassing the MYCN locus were detected in 18% of patients and were associated with a ten-year survival probability of only 5.8%. Conclusion: Using a unique large copy number dataset of high-risk neuroblastoma cases, we identified a small subset of high-risk neuroblastoma patients with extremely low survival probability that might be eligible for inclusion in clinical trials of new therapeutics. The amplicons may also nominate alternative treatments that target the amplified genes.

2018-03-13 | GSE103123 | GEO

NCTN: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

Project description:NCTN: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

| PRJNA1288590 | ENA

NCTN: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

Project description:NCTN: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

| PRJNA1288589 | ENA

Proteomic-based computational stratification of intermediate-risk prostate cancer patients.

Project description:Gleason grading is an important prognostic indicator for prostate adenocarcinoma and is crucial for patient treatment decisions. However, intermediate-risk patients diagnosed in Gleason Grade Groups (GG) 2 and GG3 can harbour either aggressive or non-aggressive disease, resulting in under- or over-treatment of a significant number of patients. Here, we performed proteomic, differential expression, machine learning, and survival analyses for 1,348 matched tumour and benign samples from 278 patients. Three proteins (F5, TMEM126B and EARS2) were identified as candidate biomarkers in patients with biochemical recurrence. Multivariate Cox regression yielded 18 proteins, from which a risk score was constructed to dichotomise prostate cancer patients into low- and high-risk groups. This 18-protein signature is prognostic for the risk of biochemical recurrence and completely independent of the intermediate GG. Our results suggest that markers generated by computational proteomic profiling have the potential for clinical applications including integration into prostate cancer management.

2023-11-30 | PXD041005 | Pride

miRNA expression profiling in high-risk neuroblastoma

Project description:In the present study we evaluated the miRNA expression profile of 31 high risk, stage 4 neuroblastoma patients.

2009-06-27 | GSE16444 | GEO